{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:57:27Z","timestamp":1794412647987,"version":"4.9.0"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effects of immunotherapy compared to chemotherapy as first\u2010 and second\u2010line treatment of advanced or metastatic urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on a published protocol, we performed a systematic search of multiple databases. Two review authors independently performed the literature selection, identified relevant studies, assessed the eligibility of studies for inclusion, and extracted data. We performed statistical analyses using a random\u2010effects model and assessed the quality of the evidence on a per\u2010outcome basis according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included five randomised controlled trials and also identified seven single\u2010arm studies. When used as first\u2010line therapy, immunotherapy probably has little to no effect on the risk of death from any cause compared to chemotherapy (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.87\u20131.07; moderate\u2010certainty evidence). immunotherapy probably has little to no effect on health\u2010related quality of life (mean difference [MD] 4.10, 95% CI 3.83\u20134.37; moderate). Immunotherapy probably reduces grade 3\u20135 adverse events (risk ratio [RR] 0.47, 95% CI 0.29\u20130.75; moderate). In the second\u2010line setting immunotherapy may reduce the risk of death from any cause (HR 0.72, 95% CI 0.63\u20130.81; low). Immunotherapy may have little to no effect on health\u2010related quality of life when compared to chemotherapy (MD 4.82, 95% CI \u22123.11 to 12.75; low). Immunotherapy may reduce grade 3\u20135 adverse events (RR 0.89, 95% CI 0.81\u20130.97; low).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to chemotherapy, immunotherapy has little to no effect on the risk of death from any cause in a first\u2010line setting. Nevertheless, it may reduce the risk of death from any cause when used as second\u2010line therapy. The health\u2010related quality of life of participants receiving first\u2010 and second\u2010line therapy does not appear to be affected by immunotherapy. Immunotherapy probably reduces or may reduce grade 3\u20135 adverse events when used as first\u2010 and second\u2010line therapy, respectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16368","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T21:33:05Z","timestamp":1713994385000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review"],"prefix":"10.1111","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-167X","authenticated-orcid":false,"given":"Philipp","family":"Maisch","sequence":"first","affiliation":[{"name":"Department of Urology, Rechts der Isar Medical Center Technical University of Munich  Munich Germany"},{"name":"Department of Urology and Pediatric Urology, University Hospital Ulm University of Ulm  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2031-124X","authenticated-orcid":false,"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology, Chonnam National University Medical School Chonnam National University Hwasun Hospital  Hwasun South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmin","family":"Kim","sequence":"additional","affiliation":[{"name":"Graduate School Yonsei University Wonju College of Medicine  Wonju South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram M.","family":"Narayan","sequence":"additional","affiliation":[{"name":"Department of Urology Emory University  Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Bakker","sequence":"additional","affiliation":[{"name":"Dr. John Archer Library University of Regina  Regina SK Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kunath","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology Klinikum Bayreuth  Bayreuth Germany"},{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-2553","authenticated-orcid":false,"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section Minneapolis VA Health Care System  Minneapolis MN USA"},{"name":"Department of Urology University of Minnesota  Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5688"},{"key":"e_1_2_8_4_1","article-title":"Robotic versus open radical cystectomy for bladder cancer in adults","volume":"4","author":"Rai BP","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)48996-8"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2638"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22031"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr156"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5534"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9761"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30900-2"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"e_1_2_8_22_1","article-title":"Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum\u2010containing chemotherapy. A Cochrane Rapid Review","volume":"7","author":"Narayan V","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_23_1","article-title":"Immunotherapy for advanced or metastatic urothelial carcinoma","volume":"10","author":"Maisch P","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch24"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch8"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch25"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.011"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30496-X"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.504"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.484"},{"key":"e_1_2_8_36_1","unstructured":"EMA restricts use of Keytruda and Tecentriq in bladder cancer"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102360"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.049"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S186271"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.002"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.04.016"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1745-8"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:10:47Z","timestamp":1761754247000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bju.16368"],"URL":"https:\/\/doi.org\/10.1111\/bju.16368","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"2024-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}